Patients side with industry on Medicare "pass-through" delay
This article was originally published in Clinica
The medical device industry has obtained the support of nine patient groups in opposing the government's increasingly cautious approach to the Medicare programme's special pass-through payments for new technology.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.